peptide
Tesamorelin
strongFDA-Approved· RxInjection
FDA-approved GH booster for reducing visceral belly fat in HIV-associated lipodystrophy. Trials showed ~15-18% visceral fat reduction. Overall weight loss is modest vs GLP-1 agonists.
Key facts
- Classification
- Tesamorelin is a 44-amino acid GHRH analog with trans-3-hexenoic acid modification.
- Primary benefits
- Fat Loss (8/10) · Muscle Growth (6/10) · Longevity (4/10)
- Administration
- Injection
- Doses studied
- 2 mg subq daily, preferably before bed. Cycle for 12-26 weeks.
- Evidence strength
- Strong — 20 peer-reviewed studies
- Stacks well with
- AOD-9604, Ipamorelin
- Legal status
- FDA-Approved · prescription required · WADA prohibited
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 20
- Stacks with
- 2 peptides
- Regulatory
- FDA-Approved
Scientific overview
Tesamorelin is a 44-amino acid GHRH analog with trans-3-hexenoic acid modification. FDA-approved for HIV-associated lipodystrophy with ~15% trunk fat reduction and improved lipid profiles. Maintains physiological GH pulsatility without GH-associated insulin resistance.
Goal coverage · Tesamorelin
🔥 Fat Loss8/10
💪 Muscle Growth6/10
⏳ Longevity4/10
😴 Sleep3/10
Medical oversight requiredNot safe during pregnancy· 4 contraindications